Abstract | BACKGROUND: SHRSP.Z-Lepr(fa)/IzmDmcr (SHRSP fatty) rats create a new animal model of metabolic syndrome. However, the renoprotective effect of telmisartan therapy and its underlying mechanisms in SHRSP fatty rats remain unknown. We evaluate the effects of long-term telmisartan therapy on renal dysfunction, podocyte injury, inflammation, and transforming growth factor-β1 (TGF-β1)/Smad, epithelial-mesenchymal transition (EMT), mitogen-activated protein kinase (MAPK), Rho-kinase, and cell-cycle progression pathway in the renal cortex of SHRSP fatty rats. METHODS: Seven-week-old male SHRSP fatty rats were treated with vehicle, telmisartan, and hydralazine for 8 weeks. Age-matched male Wistar-Kyoto/Izumo rats served as a control group. RESULTS: CONCLUSION:
|
Authors | Fumihiro Sugiyama, Naohiko Kobayashi, Mayuko Ishikawa, Sho Onoda, Toshihiko Ishimitsu |
Journal | Clinical and experimental nephrology
(Clin Exp Nephrol)
Vol. 17
Issue 4
Pg. 515-24
(Aug 2013)
ISSN: 1437-7799 [Electronic] Japan |
PMID | 23268284
(Publication Type: Journal Article)
|
Chemical References |
- Benzimidazoles
- Benzoates
- Cell Cycle Proteins
- Desmin
- Smad4 Protein
- Transforming Growth Factor beta1
- Tumor Necrosis Factor-alpha
- Hydralazine
- Telmisartan
|
Topics |
- Animals
- Benzimidazoles
(therapeutic use)
- Benzoates
(therapeutic use)
- Cell Cycle Proteins
(biosynthesis)
- Desmin
(biosynthesis)
- Epithelial-Mesenchymal Transition
(drug effects)
- Hydralazine
(therapeutic use)
- Kidney Diseases
(prevention & control)
- Male
- Metabolic Syndrome
(drug therapy)
- Nephritis
(drug therapy, metabolism)
- Podocytes
(drug effects, pathology)
- Rats
- Rats, Inbred SHR
- Rats, Inbred WKY
- Signal Transduction
(drug effects)
- Smad4 Protein
(physiology)
- Telmisartan
- Transforming Growth Factor beta1
(metabolism)
- Tumor Necrosis Factor-alpha
(metabolism)
|